Salnavak (COVID-19 coronavirus vaccine)

2022: Registration of the second nasal vaccine against COVID-19

On July 5, 2022, it became known about the registration in Russia of a nasal vaccine against the coronavirus COVID-19 called Salnavak. This is the development of the Russian company Generium.

The fact that Salnavak was included in the state register of medicines was reported by TASS with reference to this register. This preparation is a combined vector vaccine and consists of two components based on adenoviral vectors of types 26 and 5. The indication for its use is the prevention of a new coronavirus infection in adults aged 18-60 years. Vaccination should be carried out in two stages with an interval of three weeks, according to the instructions for the drug, which the agency refers to.

Russia registered the second nasal vaccine against COVID-19

The drug is injected using a special spray nozzle into the nasal cavity. The instructions indicate that use during pregnancy is possible from a 22-week period, but taking into account possible risks. The document also notes that clinical trials of the drug have not yet been completed by July 5, 2022, and the vaccine has been registered according to an accelerated scheme. It is planned to complete clinical trials of the drug at the end of December 2023.

Preclinical studies have shown that the drug causes the activation of systemic humoral and cellular immunity and forms mucosal immune protection against COVID-19 infection on the surface of the mucous membrane of the respiratory tract.

The first nasal vaccine approved by the Ministry of Health was Sputnik V from the Gamaleya Center. By July 2022, clinical trials of vaccines against coronavirus COVID-19 in nasal form are also being carried out outside Russia, their development is being carried out, for example, by the Anglo-Swedish AstraZeneca together with Oxford University and the Indian Bharat Biotech.^[1]

Notes

Шаблон:Remarks